AVBP

Company Overview — What Does ArriVent BioPharma, Inc. Do?

We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize our team’s deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is currently being evaluated in multiple clinical trials across a range of epidermal growth factor receptor (EGFR) mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a pivotal Phase 3 clinical trial in treatment naive, or first-line, patients with locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations. We received Breakthrough Therapy Designation for furmonertinib for the treatment of this disease from the U.S. Food and Drug Administration (FDA) in October 2023. A product candidate can receive Breakthrough Therapy Designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor can help to identify the most efficient path for development. The receipt of a Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and does not increase the likelihood that the product candidate will ultimately receive FDA approval for any indication. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor (TKI) that we are developing for the treatment of NSCLC patients across a broader set of EGFR mutations (EGFRm) than are currently served by approved EGFR TKIs. Furmonertinib is currently only approved and commercially distributed by Shanghai Allist Pharmaceuticals Company, Ltd. (Allist) in China as a first-line therapy to treat classical EGFRm NSCLC. The FDA has not approved furmonertinib for any use. We selected furmonertinib for global development against nonclassical, or uncommon, mutations based on preliminary reductions in tumor size observed in seven out of ten patients in first-line treatment with EGFR exon 20 insertion mutations in the ongoing Phase 1b clinical trial, the FAVOUR trial, conducted by Allist in China, and preclinical activity in P-loop and-alpha-c-helix compressing (PACC) mutations, each a subtype of uncommon mutation. In a subsequent interim data readout from the FAVOUR trial of furmonertinib in first-line patients with locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, 79% of patients (n=22 out of 28 patients) were observed to experience a reduction in tumor size of at least 30%. Allist expects to release final results of the primary analysis from the FAVOUR study in 2024. If the future clinical trial results of the FAVOUR trial are unfavorable, our clinical development plans for furmonertinib, which include conducting our global, pivotal Phase 3 FURVENT clinical trial in first-line non-squamous locally advanced or metastatic EGFRm NSCLC patients with exon 20 insertion mutations, may be adversely affected. In 2021, we licensed from Allist the right to develop and commercialize furmonertinib worldwide, with the exception of greater China, which includes mainland China, Hong Kong, Macau and Taiwan. As one of the most prevalent cancers in the world, lung cancer imposes a significant global burden on human health, and EGFRm NSCLC represents a significant proportion of those affected. Despite progress in the therapeutic landscape for EGFRm NSCLC, many patients, particularly those with uncommon mutations, such as exon 20 insertions or PACC mutations, are underserved by existing treatments. In an interim data readout from the FAVOUR trial of furmonertinib in first-line patients with locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, 79% of patients (n=22 out of 28 patients) were observed to experience a reduction in tumor size of at least 30% from the baseline in a patient without evidence of progression as measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. This measurement of reduction is the threshold in this trial for a partial response and for inclusion in determination of the overall response rate (ORR), which is the primary endpoint of this trial. In the same interim data readout, those 79% of patients were observed to experience a 15.2 month median duration of response (DOR). Interim results may not be indicative of final results; however, we believe these interim clinical results underscore furmonertinib’s potential in patients whose tumors contain an uncommon EGFRm. We were incorporated under the laws of the State of Delaware on April 14, 2021. Our principal executive offices are located at 18 Campus Boulevard, Suite 100, Newtown Square, PA. ArriVent BioPharma, Inc. (AVBP) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Zhengbin (Bing) Yao. With a market capitalization of $1.1B, AVBP is one of the notable companies in the Healthcare sector.

ArriVent BioPharma, Inc. (AVBP) Stock Rating — Reduce (April 2026)

As of April 2026, ArriVent BioPharma, Inc. receives a Reduce rating with a composite score of 33.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.AVBP ranks #2,227 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ArriVent BioPharma, Inc. ranks #259 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AVBP Stock Price and 52-Week Range

ArriVent BioPharma, Inc. (AVBP) currently trades at $25.46. The stock lost $1.79 (6.6%) in the most recent trading session. The 52-week high for AVBP is $27.22, which means the stock is currently trading -6.5% from its annual peak. The 52-week low is $15.47, putting the stock 64.6% above its annual trough. Recent trading volume was 338K shares, suggesting relatively thin trading activity.

Is AVBP Overvalued or Undervalued? — Valuation Analysis

ArriVent BioPharma, Inc. (AVBP) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.62x, versus the sector average of 2.75x.

At current multiples, ArriVent BioPharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ArriVent BioPharma, Inc. Profitability — ROE, Margins, and Quality Score

ArriVent BioPharma, Inc. (AVBP) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -49.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -45.4% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AVBP Debt, Balance Sheet, and Financial Health

ArriVent BioPharma, Inc. has a debt-to-equity ratio of 8.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 12.83x, indicating strong short-term liquidity.

AVBP has a beta of 0.91, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ArriVent BioPharma, Inc. is 47/100, reflecting average volatility within the normal range for its sector.

ArriVent BioPharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ArriVent BioPharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-4.32. Net income for the quarter was $-151M. Operating income came in at $-163M.

In FY 2025, ArriVent BioPharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-4.32. Net income for the quarter was $-166M. Operating income came in at $-178M.

In Q3 2025, ArriVent BioPharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.83. Net income for the quarter was $-35M. Operating income came in at $-38M.

In Q2 2025, ArriVent BioPharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.90. Net income for the quarter was $-31M. Operating income came in at $-34M.

Over the past 8 quarters, ArriVent BioPharma, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing AVBP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AVBP Dividend Yield and Income Analysis

ArriVent BioPharma, Inc. (AVBP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AVBP Momentum and Technical Analysis Profile

ArriVent BioPharma, Inc. (AVBP) has a momentum factor score of 61/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 1/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

AVBP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ArriVent BioPharma, Inc. (AVBP) ranks #259 out of 838 stocks based on the Blank Capital composite score. This places AVBP in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AVBP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AVBP vs S&P 500 (SPY) comparison to assess how ArriVent BioPharma, Inc. stacks up against the broader market across all factor dimensions.

AVBP Next Earnings Date

No upcoming earnings date has been announced for ArriVent BioPharma, Inc. (AVBP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AVBP? — Investment Thesis Summary

The quantitative profile for ArriVent BioPharma, Inc. suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. Price momentum is positive at 61/100, suggesting the trend favors buyers.

In summary, ArriVent BioPharma, Inc. (AVBP) earns a Reduce rating with a composite score of 33.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AVBP stock.

Related Resources for AVBP Investors

Explore more research and tools: AVBP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AVBP head-to-head with peers: AVBP vs AZN, AVBP vs SLGL, AVBP vs VMD.